BOK Financial Private Wealth Inc. Sells 4,890 Shares of Zoetis Inc. $ZTS

BOK Financial Private Wealth Inc. cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 49.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 5,080 shares of the company’s stock after selling 4,890 shares during the period. BOK Financial Private Wealth Inc.’s holdings in Zoetis were worth $792,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Zoetis by 0.5% during the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock worth $6,842,222,000 after buying an additional 189,287 shares in the last quarter. Polen Capital Management LLC boosted its holdings in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares in the last quarter. Northern Trust Corp grew its position in Zoetis by 1.2% during the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after purchasing an additional 109,791 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Zoetis by 4.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,252,697 shares of the company’s stock valued at $700,207,000 after purchasing an additional 174,119 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS opened at $120.20 on Monday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52-week low of $117.26 and a 52-week high of $181.85. The business’s 50 day moving average price is $144.21 and its two-hundred day moving average price is $152.63. The firm has a market cap of $52.97 billion, a PE ratio of 20.69, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the company posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio is presently 33.67%.

Analysts Set New Price Targets

ZTS has been the topic of several research reports. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Argus reiterated a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. UBS Group decreased their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $191.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.